174 related articles for article (PubMed ID: 32878812)
21. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707.
Maeda Y; Nishimori H; Yoshida I; Hiramatsu Y; Uno M; Masaki Y; Sunami K; Masunari T; Nawa Y; Yamane H; Gomyo H; Takahashi T; Yano T; Matsuo K; Ohshima K; Nakamura S; Yoshino T; Tanimoto M
Haematologica; 2017 Dec; 102(12):2097-2103. PubMed ID: 28971899
[TBL] [Abstract][Full Text] [Related]
22. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
23. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
[No Abstract] [Full Text] [Related]
24. Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
Nakashima J; Imaizumi Y; Taniguchi H; Ando K; Iwanaga M; Itonaga H; Sato S; Sawayama Y; Hata T; Yoshida S; Moriuchi Y; Miyazaki Y
Int J Hematol; 2018 Nov; 108(5):516-523. PubMed ID: 30032392
[TBL] [Abstract][Full Text] [Related]
25. Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.
Roswarski J; Roschewski M; Melani C; Pittaluga S; Lucas A; Steinberg SM; Jaffe ES; Waldmann TA; Wilson WH
Leuk Lymphoma; 2019 Aug; 60(8):2062-2066. PubMed ID: 30626252
[TBL] [Abstract][Full Text] [Related]
26. Adult T-Cell Leukemia/Lymphoma.
Mehta-Shah N; Ratner L; Horwitz SM
J Oncol Pract; 2017 Aug; 13(8):487-492. PubMed ID: 28796966
[TBL] [Abstract][Full Text] [Related]
27. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303.
Yamada Y; Tomonaga M; Fukuda H; Hanada S; Utsunomiya A; Tara M; Sano M; Ikeda S; Takatsuki K; Kozuru M; Araki K; Kawano F; Niimi M; Tobinai K; Hotta T; Shimoyama M
Br J Haematol; 2001 May; 113(2):375-82. PubMed ID: 11380402
[TBL] [Abstract][Full Text] [Related]
28. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
29. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study.
García-Suárez J; Bañas H; Arribas I; De Miguel D; Pascual T; Burgaleta C
Br J Haematol; 2007 Jan; 136(2):276-85. PubMed ID: 17233819
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous plaque in adult T cell leukemia/lymphoma: A case report.
Lei CS; Jiang Q; Yu Q; Qiu L
Medicine (Baltimore); 2020 Dec; 99(50):e23491. PubMed ID: 33327284
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
[TBL] [Abstract][Full Text] [Related]
33. Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol.
Gupta VG; Gogia A; Sharma V; Mallick S
Turk J Haematol; 2018 Aug; 35(3):213-214. PubMed ID: 29856361
[No Abstract] [Full Text] [Related]
34. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
[No Abstract] [Full Text] [Related]
35. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience.
Huang H; Lin Z; Lin X; Cai Q; Xia Z; Jiang W
Leuk Lymphoma; 2011 Jun; 52(6):1041-8. PubMed ID: 21599590
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
38. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma.
Fuji S; Shindo T
Stem Cell Investig; 2016; 3():70. PubMed ID: 27868052
[TBL] [Abstract][Full Text] [Related]
39. VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.
Singer JM; Mijovic A; Pettingale KW; Nethersell A; Dobbs HJ; Samaratunga IR; Lakhani A; Mufti GJ
Clin Oncol (R Coll Radiol); 1995; 7(6):366-70. PubMed ID: 8590697
[TBL] [Abstract][Full Text] [Related]
40. [Clinical outcomes of patients with peripheral T-cell lymphoma (PTCL) treated by EPOCH regimen].
Peng YL; Huang HQ; Lin XB; Xia ZJ; Li YH; Wang W; He YJ; Pan ZH; Jiang WQ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):943-6. PubMed ID: 15301720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
